ClinicalTrials.gg
CompletedNCT03385577Updated Jun 15, 2023

Yoga for Psychological Distress in Gynecologic, Gastrointestinal, or Thoracic Cancer

An interventional study of Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer in Gynecologic Cancer, Adjustment and Gastrointestinal Cancer, sponsored by University of Florida. Completed at 1 site in United States. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by University of Florida · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
Female
01

Study summary

This study will test the feasibility and acceptability of a yoga program for women with gynecologic, gastrointestinal (GI), or thoracic malignancies. This study will pilot an integrative yoga intervention that combines Western psychotherapeutic approaches with classic yogic philosophy to reduce emotional distress among women undergoing treatment for gynecologic, gastrointestinal (GI), or thoracic cancer and provide a comprehensive approach to stress management across the cancer care continuum.

Read the detailed description

Gynecologic cancers are malignancies of the female reproductive tract that affect over 70,000 women per year. Treatments for gynecologic cancer often result in numerous physical and emotional side effects that affect long-term adjustment, such as anxiety, depression, low self-esteem, sexual dysfunction, difficulties with fertility, and surgically-induced menopause. Even when initial treatments are successful, gynecologic cancers have a high recurrence rate that can reach nearly 80% among those with ovarian cancer. Fear of Cancer Recurrence (FCR) is described as one of the largest unmet psychological needs among gynecologic cancer patients and is associated with psychological distress, increased health care utilization, and functional impairment. Few studies have examined interventions designed to manage symptoms of FCR, which leaves a significant gap in the literature regarding treatment of this prominent psychosocial problem. Cancer patients report growing use of integrative medicine therapies (e.g., yoga, acupuncture, massage) to manage unmet physical and emotional needs related to their disease and treatment. The current study will take advantage of this trend in supportive oncology to investigate the feasibility and acceptability of a novel intervention program created specially to address FCR among women with gynecologic cancer. Patients will be recruited from the UF Health/Shands Hospital Gynecology Oncology Clinic and Medical Oncology clinic and invited to participate in a 10-week, manualized, small group yoga course. Psychoeducation modules, meditation training, and gentle yoga poses will be integrated into a comprehensive program focused on managing the psychosocial concerns of newly diagnosed gynecologic cancer patients. Findings from this research will contribute to the existing literature on FCR and knowledge regarding the use of integrative medicine techniques for addressing unmet psychological needs among gynecologic cancer patients. If the intervention is deemed feasible and acceptable, future research may explore ways in which this manualized yoga program compares to other psychosocial treatments for managing FCR and other forms of emotional distress in women with cancer.

02

Conditions studied

  • Gynecologic Cancer
  • Adjustment
  • Gastrointestinal Cancer
  • Thoracic Cancer

Keywords

  • Gastrointestinal (GI)
  • Fear of Cancer Recurrence (FCR)
03

In context

Gastrointestinal Neoplasms

795 studies on the registry are indexed under Gastrointestinal Neoplasms; 235 are open to participants now.

This study's enrollment of 125 is above the median of 60 across 580 interventional studies indexed under Gastrointestinal Neoplasms.

Browse Gastrointestinal Neoplasms studies →

Lead sponsor

University of Florida is the lead sponsor of 1,285 studies on the registry; 199 are open to participants now.

Of its 177 completed or terminated interventional studies of FDA-regulated products, 141 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of newly diagnosed
  • pathology-confirmed
  • (a) gynecologic cancer (e.g., cancer of the ovaries, cervix, endometrium, fallopian tubes), any stage, or
  • (b) borderline ovarian tumor, Stage II-III
  • Undergoing (or have recently undergone) surgery and/or active cancer treatment (e.g., chemotherapy, radiation, a combination of these treatments and/or another form of cancer treatment)
  • Able to read and write in English

Exclusion criteria

Exclusion Criteria:

  • History of gynecologic cancer or other cancer diagnosis (excluding basal cell or squamous cell carcinomas of the skin)
  • Current, severe, uncontrolled psychopathology (e.g., symptomatic Bipolar Disorder with a manic or depressive episode in the last six months, psychotic symptoms or disorder, or documented personality disorder)
  • History of dementia or other neurocognitive disorder that may interfere with participants' ability to adhere to study procedures
  • Poor performance status as determined by a Karnofsky Status Score \< 60,
  • For those with any childbearing potential (i.e., 18 - 62 years of age, have intact reproductive organs, and/or have not yet started chemotherapy or radiation therapy): self-reported current pregnancy, possible pregnancy, or efforts to become pregnant
  • History of regular or immersive yoga practice in the last five years defined as attending at least once weekly yoga classes for at least 6 consecutive months at any point in the prior 5 years
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Yoga Intervention

    The intervention, "Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer," is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment.

    Behavioral: Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer

Interventions

  • BehavioralStilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer

    'Stilling the waters,' the prominent theme of this program, is drawn from the core principle in yogic philosophy. It uses breath techniques and physical postures to cultivate inner peace and an ability to live in the present moment. The emphasis on stilling the fluctuations of uncertainty is a direct allusion to the intrusive and inherently unknown future, which characterizes the core experience of Fear of Cancer Recurrence (FCR). This is especially true among gynecologic, gastrointestinal (GI), or thoracic cancer patients for whom the likelihood of recurrence is quite high. An additional motif throughout the program is the lotus flower. The symbolic importance of the lotus in yogic culture is due to its requiring thick muddy waters for ideal growth. The metaphor of cancer as the muddy waters will be used to cultivate benefit-finding and acceptance regarding the mental and physical challenges participants endured during their initial diagnosis and treatment.

06

What researchers measure

Primary outcomes

  1. Feasibility of the proposed yoga program - Study enrollment rate

    Patients will complete the majority (80%) of study activities as measured by five empirically-driven indicators of feasibility.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  2. Feasibility of the proposed yoga program - Intervention session attendance

    Patients will complete the majority (80%) of study activities as measured by five empirically-driven indicators of feasibility.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  3. Feasibility of the proposed yoga program - Adherence to homework assignments

    Patients will complete the majority (80%) of study activities as measured by five empirically-driven indicators of feasibility.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  4. Feasibility of the proposed yoga program - Retention through follow-up assessment (i.e., individuals who complete all components of the study)

    Patients will complete the majority (80%) of study activities as measured by five empirically-driven indicators of feasibility.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  5. Feasibility of the proposed yoga program - Safety (i.e., adverse events)

    Patients will complete the majority (80%) of study activities as measured by five empirically-driven indicators of feasibility

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  6. Program Acceptability- Relevance of the intervention to their lives

    The majority of patients (80%) will rate five key dimensions of the intervention on a Likert scale as "Very" or "Extremely" acceptable.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  7. Program Acceptability- the Utility of the intervention to participants

    The majority of patients (80%) will rate five key dimensions of the intervention on a Likert scale as "Very" or "Extremely" acceptable.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  8. Program Acceptability- Satisfaction/Enjoyment of the intervention

    The majority of patients (80%) will rate five key dimensions of the intervention on a Likert scale as "Very" or "Extremely" acceptable.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  9. Program Acceptability - Clarity/Ease of the intervention for participants

    The majority of patients (80%) will rate five key dimensions of the intervention on a Likert scale as "Very" or "Extremely" acceptable.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  10. Program Acceptability - Plan to continue intervention exercises after completion of the study

    The majority of patients (80%) will rate five key dimensions of the intervention on a Likert scale as "Very" or "Extremely" acceptable.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

Secondary outcomes

  1. Fear of Cancer Recurrence (FCR)

    This measure will access participants' Fear of Cancer Recurrence (FCR), which includes cognitive, behavioral, and emotional experiences related to worries that their cancer will return.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  2. Cancer-Related Distress

    The Distress Thermometer will be used to assess cancer-related distress. This measure is designed to assess self-efficacy regarding distress and symptom management while facing a cancer diagnosis. Domains assessed include maintenance of activity and independence, seeking and understanding medical information, stress management, coping with treatment side effects, maintaining a positive attitude, engaging in emotion regulation, and seeking support.

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  3. State and Trait Anxiety

    Anxiety will be assessed with the State Trait Anxiety Inventory (STAI) Assesses state /trait anxiety symptoms on 4 pt. likert scale. Medium: May indicate anxiety disorder

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

  4. Depressive Symptoms

    Depressive symptoms will be assessed with the Beck Depression Inventory - Second Edition (BDI-2) - high score Suicidal Behavior

    Time frame: Pre-Intervention (Baseline) to Post-Intervention (Ten Weeks After Baseline)

07

Study locations

1 site
  • University of Florida
    Gainesville, Florida 32610, United States
08

References and documents

Publications

  • Hanvey GA, Padron A, Kacel EL, Cartagena G, Bacharz KC, McCrae CS, Robinson ME, Waxenberg LB, Antoni MH, Berry RB, Schultz GS, Castagno J, Pereira DB. Accrual and retention of diverse patients in psychosocial cancer clinical trials. J Clin Transl Sci. 2022 Apr 1;6(1):e45. doi: 10.1017/cts.2022.380. eCollection 2022. PubMed 35651964 ↗
  • Hanvey GA, Kacel EL, Bacharz KC, Wilborn AP, Mesa S, McCracken H, Estores IM, Markham MJ, Kaye FJ, Jones D Jr, George TJ, Pereira DB. Proof-of-Concept of an Integrated Yoga and Psychological Intervention in Mitigating Distress Among Diverse Women With Gynecologic, Gastrointestinal, and Thoracic Cancers. Integr Cancer Ther. 2024 Jan-Dec;23:15347354241283113. doi: 10.1177/15347354241283113. PubMed 39423043 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Nov 2022, 57 months.

Of 165 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 71. This study's 57 months is above that.

Counting every sponsor, half of 175 studies reached it within 32 months; a quarter within 16 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2017
First posted
Dec 28, 2017
StartActual
Feb 5, 2018
Primary completionActual
Nov 14, 2022
CompletionActual
Nov 14, 2022
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03385577
Responsible party
Sponsor
First posted
Dec 28, 2017
Start date
Feb 5, 2018
Primary completion
Nov 14, 2022
Completion
Nov 14, 2022
Last update
Jun 15, 2023

Study contacts

Deidre B. Pereira, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion